Expression systems for the production of recombinant pharmaceuticals.
The new generation of biological products are largely the result of genetic engineering. The qualitative and quantitative demand for recombinant proteins is steadily increasing. Molecular biologists are constantly challenged by the need to improve and optimise the existing expression systems, and also develop novel approaches to face the demands of producing the complex proteins of tomorrow. This continuous evolution is paralleled by growing concerns about the safety of these novel pharmaceuticals, with health authorities setting high standards for certification. One of the strategies used by researchers in this field involves sourcing new genetic elements for incorporation into expression systems by systematically analysing the rich natural diversity of microorganisms and plant-based expression systems. There are, in addition, numerous tools for modifying microorganisms and for re-engineering existing biological pathways or processes to meet the needs of the pharmaceutical industry. The aim of this review is to present the conventional and alternative expression systems, focusing on prokaryotic expression systems and briefly exploring other complementary recombinant protein production systems and their unique features.
Sodoyer
Régis
R
Molecular Biology - Research Department, Aventis Pasteur, Marcy l'Etoile, France. Regis.sodoyer@aventis.com
D000818:Animals; D005057:Eukaryotic Cells / Q000378:metabolism; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D011387:Prokaryotic Cells / Q000378:metabolism; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000235:genetics
D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins